Retatrutide is supplied by RS Bio Labs strictly as a laboratory research material for qualified scientific personnel. It is not approved, intended or authorised for human consumption, self-administration, diagnostic, therapeutic or veterinary use. All findings referenced here are from published preclinical or clinical-trial literature and do not constitute medical advice or establish safety in any unapproved setting.
Development stage at a glance
Retatrutide is an investigational compound: its Phase 2 programme is complete and reported, while the pivotal Phase 3 TRIUMPH programme remains ongoing. It has not been approved by the MHRA, FDA or any other regulator, and it is not available as a medicine. The summary below draws together the published data across the development pipeline — pharmacokinetics, obesity, liver disease and glycaemic control — so the evidence can be read in one place. For the underlying biology, see What Is Retatrutide?; for the chronology, see the history of Retatrutide.
Phase 1: first-in-human safety & pharmacokinetics
The first-in-human work (2021–2022) established the compound's basic safety and pharmacokinetic profile in single- and multiple-ascending-dose studies. These trials characterised a long elimination half-life of approximately six days — a consequence of the C20 fatty-acid conjugation and albumin binding — which supports a once-weekly research dosing schedule. Early signals of dose-dependent weight reduction and glucose lowering were observed, providing the rationale for the larger Phase 2 programme. The pharmacokinetics are covered in more depth in the half-life guide.
Phase 2 obesity: the TRIUMPH-1 trial
The landmark Phase 2 obesity study — TRIUMPH-1 (Jastreboff et al., New England Journal of Medicine, 2023) — evaluated Retatrutide in adults with obesity over 48 weeks. At the highest 12 mg dose, mean body-weight reduction reached approximately 24.2%. The response was clearly dose-dependent, and critically the weight-loss curve had not plateaued by week 48, implying the full effect may exceed what was captured within the trial window. This is the single most cited result in the Retatrutide literature and the largest reported for any incretin-class compound to date.
For comparison, Semaglutide (GLP-1) reported ~15% and Tirzepatide (GIP/GLP-1) ~22.5% in their pivotal trials. Retatrutide's ~24.2% at 48 weeks — still trending downward — is what places the triple-agonist mechanism at the frontier of incretin research. See Retatrutide vs Tirzepatide.
Phase 2 MASH & liver-fat programme
A parallel Phase 2 programme studied Retatrutide in metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). The reports described substantial reductions in hepatic fat content, with a large proportion of participants reaching normalisation of liver fat on imaging. The glucagon-receptor arm of the triple mechanism — associated with hepatic lipid mobilisation and increased energy expenditure — is the pathway most implicated in this liver-directed effect, distinguishing Retatrutide from GLP-1-only and GIP/GLP-1 compounds.
Type-2-diabetes glycaemic findings
A separate Phase 2 study in adults with type 2 diabetes assessed glycaemic control alongside weight. Retatrutide produced marked reductions in HbA1c together with meaningful weight loss across the dose range, consistent with the combined insulinotropic (GIP/GLP-1) and metabolic (glucagon) actions of the molecule. These data support its investigation as a metabolic compound rather than a weight-loss agent alone.
Ongoing Phase 3: the TRIUMPH programme
Development has advanced into the pivotal Phase 3 TRIUMPH programme — a suite of trials spanning obesity, obesity with comorbidities, and importantly a dedicated cardiovascular outcomes study. These trials are designed to confirm the durability of the Phase 2 weight effect, evaluate longer-term safety, and establish whether the metabolic benefits translate into hard clinical outcomes. Results are pending; until they report and any regulator reviews them, Retatrutide remains investigational.
Adverse events
Across the reported trials the adverse-event profile was predominantly gastrointestinal and dose-dependent — most commonly nausea and reduced appetite — consistent with the wider incretin class. These effects were generally mild to moderate and were mitigated by gradual dose titration, which is the standard approach used to improve tolerability across GLP-1-based compounds.
| Study / Phase | Focus | Headline finding |
|---|---|---|
| TRIUMPH-1 (Ph2) | Obesity | ~24.2% mean weight reduction at 12 mg / 48 wk |
| Phase 2 MASH | Liver fat | Marked reduction in hepatic fat content |
| Phase 1 | Safety & PK | Half-life ~6 days; supports weekly dosing |
| Phase 3 TRIUMPH | Obesity + CV outcomes | Ongoing |
How to read this
Everything above is a summary of published preclinical and clinical-trial literature, provided as a scientific reference only. Trial data — however striking — does not establish safety in any unapproved setting and does not constitute medical advice. Retatrutide has not been evaluated by the MHRA or FDA for any use. Products sold by RS Bio Labs are research reagents for in vitro laboratory work and are not for human use.